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Edited by Laszlo NagyAbstract The modiﬁcation of homeodomain-interacting protein
kinase 2 (HIPK2) by small ubiquitin-like modiﬁer 1 (SUMO-1)
plays an important role in its targeting into the promyelocytic leu-
kemia body, as well as in its diﬀerential interaction with binding
partner, but the desumoylation of HIPK2 by SUMO-speciﬁc pro-
teases is largely unknown. In this study, we show that HIPK2 is a
desumoylation target for the SUMO-speciﬁc protease SENP1
that shuttles between the cytoplasm and the nucleus. Mutation
analyses reveal that SENP1 contains the nuclear export sequence
(NES) within the extreme carboxyl-terminal region, and SENP1
is exported to the cytoplasm in a NES-dependent manner.
Sumoylated HIPK2 are deconjugated by SENP1 both in vitro
and in cultured cells, and the desumoylation is enhanced either
by the forced translocation of SENP1 into the nucleus or by the
SENP1 NES mutant. Concomitantly, desumoylation induces dis-
sociation of HIPK2 from nuclear bodies. These results demon-
strate that HIPK2 is a target for SENP1 desumoylation, and
suggest that the desumoylation of HIPK2 may be regulated by
the cytoplasmic-nuclear shuttling of SENP1.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The homeodomain-interacting protein kinase 2 (HIPK2)
both interacts with and phosphorylates a variety of transcrip-
tion factors, including homeoproteins, the Groucho corepres-
sor, CtBP1, Myb, and p53, all of which represent critical
regulators of cell fate decisions and apoptosis during develop-Abbreviations: HIPK2, Homeodomain-interacting protein kinase 2;
SUMO, small ubiquitin-like modiﬁer; Myc-tag, Myc-epitope tag;
PML, promyelocytic leukemia; GST, glutathione S-transferase; DAPI,
4 0,6-Diamidino-2-phenylindole; LMB, Leptomycin B; NES, nuclear
export sequence; NLS, nuclear localization sequence; NB, nuclear
body; GFP, green ﬂuorescent protein
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doi:10.1016/j.febslet.2005.10.010ment [1–7]. As such, studies of the HIPK2 knock-out mice have
revealed that HIPK2 is a critical component of transcriptional
machinery that controls sensory neuron survival [8,9]. HIPK2
is the ﬁrst protein kinase shown to be modiﬁed by small ubiq-
uitin-like modiﬁer 1 (SUMO-1) [10]. The sumoylation of
HIPK2 occurs at multiple sites, and aﬀects its interactions with
binding partners, as well as its stability and recruitment into the
promyelocytic leukemia (PML) body [11–13]. To date, how-
ever, little is known about desumoylation of HIPK2.
A growing number of proteins have been designated as tar-
gets of the SUMO-modiﬁcation system [14,15]. The SUMO
conjugation pathway has been shown to employ a series of en-
zymes that exhibit sequence similarity to analogous enzymes
within the ubiquitin pathway, and also utilizes similar
biochemical mechanisms [16]. Like ubiquitin system, SUMO-
modiﬁcations appear to be dynamic and reversible. As predicted,
the ﬁrst SUMO-speciﬁc protease, Ulp1, has been identiﬁed in
yeast recently [17]. Thereafter, many SUMO-speciﬁc proteases
are now known in mammals, which share sequence similarity
in their C-terminal domains with the catalytic Ulp domain of
yeast Ulp1 [16,18,19]. However, desumoylation targets for
SUMO-speciﬁc protease are largely unknown and begun to
be identiﬁed. One of the interesting features of the SUMO-spe-
ciﬁc proteases is their subcellular localization. Yeast Ulp1 and
Ulp2 are detected at the nuclear pore and nucleoplasm, respec-
tively [20,21]. The mammalian SENP1 is localized mainly in
the nucleus [18], and the nuclear localization sequence (NLS)
of SENP1 was recently characterized [22]. SENP3 is localized
in the nucleolus whereas SUSP1/SENP6 is localized in the
cytoplasm [23,24]. In the case of SENP2, the largest SENP2/
Axam is associated with the nucleoplasmic face of nuclear pore
[25]. The shorter isoforms Axam2 and SuPr-1, which lack the
N-terminal NPC targeting sequence, were detected in the cyto-
plasm and the PML bodies, respectively [26,27]. Therefore, the
distinct subcellular localizations of these proteins may target
them toward discrete sets of substrates, thereby allowing for
the selective deconjugation of SUMO-modiﬁed proteins [14].
However, domains and factors regulating subcellular localiza-
tion of SUMO-speciﬁc proteases are less understood.
In this report, we have demonstrated that HIPK2 is a desu-
moylation target for SENP1. Furthermore, we have shown
that, depending on diﬀerent cell types, SENP1 can be localized
either in the cytoplasm or in the nucleus, and that SENP1 is
exported to the cytoplasm through the nuclear export sequenceblished by Elsevier B.V. All rights reserved.
Y.H. Kim et al. / FEBS Letters 579 (2005) 6272–6278 6273(NES) which maps to the carboxyl-terminal end of the protein.
Our results provide a potential mechanism by which desumoy-
lation of HIPK2 can be regulated through the cytoplasmic-
nuclear shuttling of SENP1.2. Materials and methods
2.1. Cell culture, transfection and Western blot
U2OS and CV-1 cells were grown in Dulbeccos modiﬁed Eagles
medium, supplemented with 10% fetal bovine serum. For immunoblot
analysis, CV-1 cells were seeded onto six-well plates, and DNA trans-
fection was carried out using the N,N-bis-(2-hydroxyethyl)-2-aminoe-
thanesulfonic acid-buﬀered saline version of the calcium phosphate
method. Western blots were performed with indicated antibodies as
described previously [10].
2.2. Plasmid construction and site-directed mutagenesis
Myc-HIPK1, Myc-HIPK2, and EGFP-SUMO-1 were described pre-
viously [1,10]. The Myc-SENP1 plasmid was constructed by the inser-
tion of cDNA, which is ampliﬁed by PCR using template DNAs from
the human placenta cDNA library (Clontech), into the EcoRI and XbaI
sites of pCS3MT.TheMyc-SENP1(C603A) andEGFP-SENP1NES-M
mutants were generated using the QuickChange mutagenesis kit (Strat-
agene) according to the manufacturers recommendations. All muta-
tions were veriﬁed by DNA sequencing. EGFP-2x SENP1 NES was
constructed by the insertion of double strand oligonucleotides
(5 0-AATTCATGGTCTGGGAGATCCTCCACCGAAAACTCCTC-
GTCGACATGGTCTGGGAGATCCTCCACCGAAAACTCTTGTG-
AG-3 0) encoding two copies of SENP1 NES (MVWEILHRKLL) into
the EcoRI and SalI sites of pEGFP-C2 (Clontech).
2.3. Generation of transgenic ﬂy lines
The DNA fragments encoding wild-type SENP1 were excised from
EGFP-SENP1, and were introduced into the EcoRI/XbaI sites of the
P-element vector pUAST [28]. The transgenic lines harboring UAS-
GFP-SENP1 were established using standard procedures as described
[29]. Five diﬀerent transgenic lines for wild-type SENP1 were estab-
lished, and at least two distinct transgenic lines were crossed with
the fkh-GAL4 driver line [30] to investigate the potential variations
of SENP localizations in vivo. Fly growth and cross of transgenic lines
were conducted at 25 C according to the standard procedures.Fig. 1. Nuclear or cytoplasmic localization of SENP1. (A) Plasmids
encoding HA-tagged human SENP1 were transfected into U2OS and2.4. Immunocytochemistry
CV-1 cells were grown on coverslips and transfected with the Myc-
HIPK2 and GFP-SENP1 expression vectors. Thirty-six hours after
transfection, cells were ﬁxed for 15 min with 10% formaldehyde at room
temperature, then incubated with a solution containing 1· PBS and
0.5% Triton X-100. All subsequent procedures were done as described
previously [10]. In order to obtain the images of GFP-SENP1 in the sal-
ivary gland, the salivary gland and its associated tissues were isolated
from third instar larvae, followed by ﬁxation and staining using 4 0,6-
diamidino-2-phenylindole (DAPI). The GFP-SENP1 andDAPI images
were acquired with a confocal laser scanning microscope, a Zeiss
LSM510. The acquired images were then processed with Adobe
Photoshop. For time-lapse imaging of living cells, CV-1 cells were
transfected with GFP-SENP1. After 24 h transfection, cells were trea-
ted with Leptomycin B, and images of cells were taken at diﬀerent time
points.CV-1 cells. The cells were then ﬁxed and incubated with anti-HA
antibody, and followed by detection with rhodamine-conjugated anti-
mouse secondary antibody. The nuclear or cytoplasmic localization of
SENP1 was assessed via comparison with DAPI staining images. (B)
The GFP-SENP1 plasmids were transfected into CV-1 cells. Thirty-six
hours after transfection, LMB was applied to the cells. A typical image
was obtained with a confocal laser scanning microscope, at 50 and
100 min after LMB treatment. The nuclear relocalizations of GFP-
SENP1 are shown with arrows. (C) The UAS-GFP-SENP1 transgenic
lines were crossed with the fkh-GAL4 driver lines. A typical image of
GFP-SENP1 was acquired from the salivary gland (SG) and the
proventriculus (PV) of the Drosophila third instar larvae. The nuclei of
the cells were decorated with DAPI staining.2.5. In vitro desumoylation
GST-SENP1 fusion proteins were expressed in Escherichia coli and
puriﬁed with a glutathione–Sepharose column according to manufac-
turers protocol. For the isolation of the SUMO-modiﬁed HIPK2 as
a substrate of the in vitro reaction, cells were cotransfected with
Myc-HIPK2 and GFP-SUMO-1 expression vectors. Subsequently,
Myc-HIPK2 proteins (both modiﬁed and unmodiﬁed-HIPK2) were
immunoprecipitated with anti-Myc antibodies and diluted in the reac-
tion buﬀer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, and 1 mM dithi-
othreitol). Increasing amounts of GST-SENP1 (1 or 2 lg) were addedand the mixture was incubated at 37 C for 1 h. The desumoylation of
the HIPK2-SUMO-1 conjugates was detected by Western blotting
using anti-Myc antibodies.3. Results
3.1. Nuclear or cytoplasmic localization of SENP1
HIPK2 conjugation by SUMO-1 plays an important role in
the localization of HIPK2 [10,13], as well as its diﬀerential
interactions with binding partners [11]. In order to gain insight
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characterize the enzyme responsible for the desumoylation of
HIPK2. Among known SUMO-speciﬁc proteases, SENP1
was chosen to study because it seems to be the most eﬀective
with regard to the removal of SUMO-1 moiety from sumoy-
lated HIPK2 (data not shown). During this study, we found
that SENP1 localized in either the cytoplasm or nucleus,
depending on the cell type (Fig. 1). HA-tagged human SENP1
was found to localize mainly in the cytoplasm of the CV-1
cells, whereas it localized in the nucleus of the U2OS cells
(Fig. 1A). These results indicated that the subcellular localiza-
tion of SENP1 could be changed, depending on the cellular
context. In order to determine whether SENP1 can be
exported from the nucleus, CV-1 cells were transfected with
GFP-SENP1. After 24 h transfection, cells were treated with
Leptomycin B (LMB), an inhibitor of the nuclear export factor
CRM1, and green ﬂuorescent protein (GFP) signals from
transfected living cells were monitored. All of the visible
GFP-SENP1 was retained in the nucleus 100 min after the
application of LMB (Fig. 1B). This result indicated that theFig. 2. Characterization of the NES motif of SENP1. (A) Schematics of the
before and after LMB treatment are summarized to the right of the schemat
cytoplasm (C) is marked as follows: +/, barely detectable; +, weak; ++, med
CV-1 cells, and typical images were obtained for each mutant both before and
plasmids were transfected into CV-1 cells along with Myc-HIPK2 and His-SU
well as the extent of HIPK2 sumoylation, were determined with Western bl
amino acids corresponding to SENP1 NES were aligned with those of the rel
amino acids are boxed and the amino acids mutated in the SENP1 NES-M a
encoding EGFP and EGFP-SENP1 NES fusion protein, respectively, we
transfection.LMB blocked nuclear export of GFP-SENP1, and suggests
that SENP1 shuttles between the cytoplasm and the nucleus.
In order to further explore the localization patterns of SENP1
in vivo, we generated transgenic ﬂy lines harboring a GFP-
SENP1 transgene. The transgenic lines were crossed with the
fkh-GAL4 driver lines in order to induce expression of GFP-
SENP1 in the salivary gland and the gut primordia of the
Drosophila third-instar larvae [30]. In the salivary gland,
GFP-SENP1 localized to both the nucleus and the cytoplasm
including the plasma membrane, whereas GFP-SENP1 existed
predominantly in the cytoplasms of the cells comprising the
proventriculus, a glandular portion of the foregut (Fig. 1C).
These results clearly indicate that GFP-SENP1 can be local-
ized in either the nucleus or cytoplasm, depending on the cel-
lular context and can shuttle between the nucleus and the
cytoplasm (or plasma membrane) in vivo.
3.2. Characterization of NES of SENP1
The ﬁnding of the relocalization of cytoplasmic GFP-
SENP1 into the nucleus upon treatment of LMB compelledvarious SENP1 deletion and point mutants. Their localizations both
ics. Intensity of GFP signal detected either in the nucleus (N) or in the
ium, +++, strong. (B) The GFP-SENP1 mutants were transfected into
after the application of LMB treatment. (C) The GFP-SENP1 mutant
MO-1 expression plasmids. The levels of SENP1 mutant expression, as
otting using anti-GFP and anti-Myc antibodies, respectively. (D) The
ated SUMO-speciﬁc proteases as indicated in the ﬁgure. The conserved
re marked as asterisks. (E) The EGFP-C2 and 2xNES-EGFP plasmid
re transfected into CV-1 cells, and images were obtained 36 h after
Fig. 3. Nuclear diﬀusion of HIPK2 upon the relocalization of SENP1.
CV-1 cells were transfected with plasmids encoding Myc-HIPK2 alone
or along with plasmids encoding GFP-SENP1. The transfected cells
were ﬁxed and stained with anti-Myc antibody. Myc-HIPK2 was
visualized by the incubation of the cells with rhodamine-conjugated
anti-mouse IgG. The nuclei of the cells were decorated with DAPI
staining. The arrowhead and arrow indicate the cell expressing SENP1
alone and the cell expressing both SENP1 and HIPK2, respectively.
Y.H. Kim et al. / FEBS Letters 579 (2005) 6272–6278 6275us to attempt to map the motif responsible for SENP1 nuclear
export. We constructed and transfected a variety of GFP-
SENP1 deletion mutants into CV-1 cells, and examined the
localizations of SENP1 mutants (Fig. 2A). The deletion of
the C-terminal portion to aa 634 induced the nuclear localiza-
tion of SENP1 (Fig. 2B, DC1), suggesting that the motif for
SENP1 export is located in this region. Further deletion to
aa 574 resulted in the diﬀused localization of SENP1 both to
the nucleus and the cytoplasm (Fig. 2B, DC2), and this distri-
bution persisted unchanged after treatment of LMB. This re-
sult suggests that there might be a motif for the nuclear
localization of SENP1 in the region from aa 574 to 633
(Fig. 2B). The amino acid alignment of C-terminal portion
of SENP family proteins indicated that some speciﬁc amino
acids are particularly well-conserved between various SENP
family proteins, and some portion of these sequences exhibited
a profound similarity with the NES motif of IjB (Fig. 2D). In
order to conﬁrm the function of the NES motif, the conserved
amino acids of M634, I638 and the L643 of SENP1 were
substituted with alanines. The resulting SENP1 NES-M mu-
tant was preferentially localized to the nucleus of the CV-1
cells, irrespective of LMB treatment (Fig. 2B). This ﬁnding
strongly suggests that the NES motif is located within the ex-
treme C-terminus, and also that SENP1 might be exported via
this motif. This NES motif appears to be rather well-conserved
between Drosophila, mouse, and human SENP1, and between
SENP1, SENP2, and SENP3 (Fig. 2D), suggesting that nucle-
ar export is vitally important for the regulation of several
members of the SUMO-speciﬁc proteases family as well as
for the regulation of SENP1. The conserved SENP1 NES
(MVWEILHRKLL) was suﬃcient to export GFP when two
copies of the NES was fused to the C-terminal EGFP
(Fig. 2E). The nuclear localization of the catalytic mutant
SENP1(C603A) was consistent with the ﬁnding reported previ-
ously [22]. The desumoylation activities of the SENP1 mutants
were analyzed with Western blotting using anti-Myc antibod-
ies (Fig. 2C). The NES-M SENP1 mutant exhibited a much
more pronounced desumoylation activity toward the HIPK2-
SUMO conjugates than did the wild-type SENP1 (Fig. 2C,
lane 5), which was consistent with the results seen with the
application of LMB treatment (see below, Fig. 4D). The
DC1 SENP1 mutant was not found to remove the SUMO-1
moiety from the HIPK2-SUMO conjugates, despite its nuclear
localization. This suggests that the residues for SENP1 cata-
lytic activity might be deleted in this mutant. When all of these
results are considered, it would appear that both the nuclear
localization signal and the NES of SENP1 might function to
determine the location of SENP1 in cultured cells.
3.3. Desumoylation of HIPK2 by SENP1
As HIPK2 sumoylation aﬀects its localization within the nu-
cleus, we initially attempted to visualize HIPK2 localization in
the presence of SENP1. CV-1 cells were transfected with the
plasmids expressing Myc-HIPK2 alone and with both plasmids
encoding Myc-HIPK2 and GFP-SENP1. As previously de-
scribed, HIPK2 was localized to the discrete dot structure
[10], and GFP-SENP1 was predominantly localized to the cyto-
plasm (Fig. 3, arrowhead). However, the GFP-SENP1 was
translocated into the nucleus upon HIPK2 co-expression. In
addition, HIPK2 exhibited a diﬀused localization pattern in
the nucleoplasm with the relocalization of SENP1 (Fig. 3,
arrow). HIPK2 desumoylation as the result of SENP1s activitywas evaluated with Western blot analysis following cotransfec-
tion with increasing amounts of SENP1 plasmids, along with
Myc-HIPK2 and GFP-SUMO-1 expression plasmids. The ex-
pressed SENP1 was noted to deconjugate the SUMO-1 from
the sumoylated HIPK2 in direct proportion to the amounts
of SENP1 expressed (Fig. 4A). In order to explore these obser-
vations in further detail, we conducted two experiments, involv-
ing the in vitro desumoylation of HIPK2 and desumoylation
using the catalytic mutant SENP1(C603A) in cultured cells.
The aﬃnity-puriﬁed GST-SENP1 was shown to eﬀectively re-
move SUMO-1 moiety, in the presence of Ca2+ rather than
Mn2+, from the sumoylated HIPK2 which had been prepared
via the immunoprecipitation of lysates using anti-Myc anti-
body, from cells transfected with Myc-HIPK2 and GFP-
SUMO-1 (Fig. 4B). Our ﬁndings in this regard indicated that
the desumoylation of HIPK2-SUMO conjugates was induced
as the result of the direct catalytic activity of SENP1. In order
to conﬁrm the SENP1-speciﬁc desumoylation of HIPK2-
SUMO conjugates in cultured cells, plasmids encoding wild-
type His-SENP1 and the C603A mutant were transfected into
CV-1 cells, in combination with plasmids expressing Myc-
HIPK2 and GFP-SUMO-1. The cell lysates were then
subjected to Western blotting using anti-GFP, anti-His and
anti-Myc antibodies, in an attempt to detect cellular SUMO-
conjugates, His-SENP1 and Myc-HIPK2, respectively. The
wild-type SENP1 was determined to eﬃciently desumoylate cel-
lular SUMO-conjugates, including the sumoylated HIPK2.
However, the catalytically inactive mutant, SENP1(C603A),
was determined to be unable to desumoylate HIPK2-SUMO
conjugates and the cellular sumoylated proteins, and also
exhibited a dominant negative eﬀect antagonizing the functions
of endogenous SENP1, in which the SUMO-conjugation of
HIPK2 was comparably increased (Fig. 4C, lane 6). These
Fig. 4. Desumoylation of HIPK2-SUMO conjugates by SENP1. (A) Increasing amounts of the His-SENP1 plasmids were cotransfected into CV-1
cells together with the Myc-HIPK2 and GFP-SUMO-1 expression plasmids. The sumoylated HIPK2 were visualized with Western blotting using
anti-Myc antibodies. (B) The sumoylated HIPK2 were immunoprecipitated from the lysates of cells transfected with the Myc-HIPK2 and GFP-
SUMO-1 plasmids, and were subsequently used for in vitro desumoylation reactions in the presence of aﬃnity-puriﬁed GST-SENP1, with Mn2+ or
Ca2+ as a cofactor. (C) The wild-type SENP1 and C603A mutant plasmids were transfected into CV-1 cells, together with Myc-HIPK2 and
GFP-SUMO-1. Both the sumoylated HIPK2 and the expressed wild-type or mutant SENP1 were detected with Western blotting using anti-Myc and
anti-His antibodies, respectively (right panel). The total cellular SUMO-conjugates were visualized with anti-GFP antibodies (left panel). (D) CV-1
cells were transfected with Myc-HIPK2 and GFP-SUMO-1 plasmids along with or without His-SENP1 plasmids. Twenty-four hours after
transfection, cells were treated with LMB for 6 h before Western blotting using anti-Myc antibodies (left panel). The total SUMO conjugates in the
cells were detected with anti-GFP antibodies (right panel).
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moylation of the HIPK2-SUMO conjugates. Taken together,
SENP1 can act as a desumoylation enzyme for HIPK2-SUMO
conjugates, both in vitro and in vivo. As sumoylations are nu-
clear events and most SUMO-conjugates are located within the
nucleus, it appears that SENP1 might ﬁnd its cellular targets
subsequent to its nuclear relocalization. Therefore, we assessed
the desumoylation of both HIPK2 and its cellular targets sub-
sequent to the administration of LMB treatment. Indeed, as
shown in Fig. 4D, LMB treatment enhanced the removal of
SUMO-1 moiety from both HIPK2-SUMO-1 conjugates and
the cellular proteins-SUMO-1 conjugates. This ﬁnding is con-
sistent with the increased desumoylation of HIPK2-SUMO
conjugates by SENP1 NES-M mutant (Fig. 2C, lane 5). Taken
together, we conclude that HIPK2-SUMO conjugates are eﬃ-
ciently desumoylated as the result of SENP1 relocalization.4. Discussion
We and others have previously demonstrated that HIPK2 is
recruited into the PML body, during which the sumoylation
of both PML and other nuclear body (NB) components appears
to be vitally important [10,13]. The assembly and disassembly of
PML bodies is known to be an extremely dynamic process,
which is dependent upon a host of signaling cues and cellular
stresses, including heat shock and Cadmium [31,32]. In this
paper, we have shown that HIPK2-SUMO conjugates are the
direct target of SENP1, and also that SENP1 itself is capable
of shuttling between the cytoplasm and the nucleus. Bailey
and OHare [22] reported that the catalytic mutant SENP1-
(C603A) was localized to the nucleus and was recruited into
NB upon the co-expression of PML. The PML-SUMO conju-
gates were also determined to be the target of SENP1 [18].
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conjugates form a complex with SENP1 in the NBs, and that
the balance between sumoylation and desumoylation is vitally
important with regard to the dynamics of NBs. In support of
this notion, we determined that HIPK2 was released from
NBs to a diﬀused nucleoplasmic localization via the co-
expression of SENP1 (Fig. 3). In addition, SENP1(C603A)
was determined to function as a dominant negative mutant,
and resulted in an enhancement of HIPK2 sumoylation
(Fig. 4C). These data, when combined with our observations
of the desumoylation of HIPK2-SUMO conjugates, both
in vitro and in vivo, compelled us to conclude that SENP1 is
responsible for the deconjugation of SUMO-1 from the sumoy-
lated HIPK2. We also observed that the SUMO-1 moiety was
removed from the sumoylated HIPK2 in the cultured cells by
the activity of SuPr-1 and Axam-2, although this took place
to a lesser extent (data not shown), which is consistent with a
very recent study [33]. As the case of PML, therefore, it is con-
ceivable that more than two SUMO-speciﬁc proteases might
serve to regulate HIPK2 desumoylation.
To the best of our knowledge, this paper is the ﬁrst to dem-
onstrate that SENP1 is exported to the cytoplasm in a
CRM1- and C-terminal NES-dependent manner. As shown
in Fig. 1B, GFP-SENP1 was localized in the cytoplasm but
relocalized into the nucleus after the application of LMB treat-
ment, indicating the nucleo-cytoplasmic shuttling of SENP1.
Amino acid sequence analysis also indicates that there may
be three potential NLSs (KKTGRR172–177, KKRK574–577 and
PYFRKRM628–634) within SENP1. Among them, KKTGRR
(aa 172–177) motif was analyzed previously [22]. In our study,
the DC2 SENP1 mutant, which lacked both KKRK (aa 574–
577) and PYFRKRM (aa 628–634), was shown to be localized
in both the nucleus and the cytoplasm, and the DC1 SENP1
mutant, which lacked both NES and PYFRKRM (aa 628–
634), was determined to be localized predominantly in the nu-
cleus (Fig. 2B). These results suggest that each NLS alone is
insuﬃcient for the nuclear localization of SENP1, and that
the two or three NLSs must work in concert to ensure the nu-
clear localization of SENP1. These explanations are also con-
cordant with the observation that the KKTGRR172–177 motif
alone was insuﬃcient for the localization of pyruvate kinase
into the nucleus [22]. The C-terminal region of SENP1 is com-
posed of the catalytic core domain of SENP1, containing two
NLSs and one NES. SENP1 localization was also apparently
inﬂuenced by the catalytic activity of SENP1. The SENP1-
(C603A) mutant was shown to be localized within the nucleus
(Fig. 2B), and evidently relocated to the dot structure upon
the co-expression of PML or HDAC4 [22]. These ﬁndings
showed that the catalytic activity of SENP1 and its interaction
with binding partners are factors which help to determine the
localization of SENP1. Although SENP1(C603A) mutant
shows additional band that probably generated by sumoyla-
tion, it is not clear whether the sumoylation of SENP1 is
involved in nuclear-cytoplasmic shuttling of SENP1. SENP1
localization could clearly be changed as the result of shifts in
the balance between nuclear import and export, as well as of
molecular interactions with targets. Consistent with this idea,
co-expression of adenoviral E1A, which was shown to cooper-
ate with E1B, which is sumoylated, for cellular transformation
[34], induced the nuclear localization of SENP1 (data not
shown). Probably, SENP1 localization might be controlled by
the extracellular signaling pathway [35], and that concurrentpost-translational modiﬁcations such as sumoylation or phos-
phorylation might add the ﬁne control and complexity to the
regulation of SENP1.
The NES motif of SENP1 identiﬁed in this study appears to
be quite well-conserved among the other members of the
SENP family, including SENP2/Axam, SuPr-1, SENP3 and
SENP5 (Fig. 2D). Interestingly, cytoplasmic SENP proteins
such as SUSP1/SENP6 and SUSP2/SENP7 [23] contain no
conserved NES within their C-terminal regions, but all nuclear
SENP proteins harbor the NES motif, although they exhibit
diﬀerent localizations, in either the nuclear membrane, the
PML body, or the nucleolus [15,36]. This raises a possibility
that all nuclear SENP proteins might be exported depending
on the cellular contexts and existence of environmental stimuli,
as the case of SENP1. Further studies might provide more in-
sight into the relevance of the conservation of the NES motif
among members of SENP family.
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